Member Info for ForFXSake

in case the price *drops* on anticipation of selling

Yes. I overlooked that too.

1.45p is the point at which you start to speculate without being at a loss. So realistically, no one is going to buy until the price is comfortably above that level. By the same rule, they might not want to hang on to them for too long after exercising, in case the price on anticipation of selling (unless they are very close to expiry).

So DG & JH would be better off buying theirs now instead of waiting for the price to go back above 4p ;0)

I certainly won't begrudge them it if they can get the price moving up to a respectable level very soon and don't sell out to any cheeky low-bidding chancers that might happen along in the meantime.

If the price is below or at 4p come October then they will expire and it'll will have cost her nothing. Let's not forget JH and DG also got a fat salary of 9 or 10k a month alongside their warrants.

In that situation, having warrants is a little bit different to committing your own money upfront. There is no risk. You just exercise them if it's opportune to do so. The only punishment is not to be rewarded a bonus over and above your salary.

It might be different for the 3 current board members if this is their only remuneration. In that case, they would have worked for nothing if the warrants came to nought. So there is bit more of an incentive to appreciate the price. However, 1.45p should not be too high a target to hit so it perhaps not that risky.

I just hope they're greedy and want the highest price possible.

How fortunate that the price is so low.

We might be tiny but if we're a paying client then why should our deadlines have to be any less rigid than any other paying clients of this CRO?

As for "turning the company around". I have yet to see tangible evidence of that while the shareprice still languishes at a 3rd of what is was when the last CEO joined!

I get the feeling I've missed out on a hat sandwich today.

Let's not forget that one of those pivotal bits of news should have been delivered in December. That didn't happen so we got excuses that it would be January. I wasn't too worried about that at first. I thought the last CEO would still be around to see things through. Then we get further slippage to early 2022 and we find out from Soup that the CEO finished in mid-December and, to rub salt in the wound, possibly started work for her new employer even earlier than that!

The last CEO had one job, to deliver the complete data package before leaving. Unfortunately it seems that it wasn't the dream job.

When will the disappointment and blather actually end?

"That's the level of buying we've been waiting for! "

Indeed. Nice 90k GBP buy

"AGM is on Monday so probably news after that"

I agree that it's unlikely to be before then.

Everything is probably pivotal on securing the Lanstead funding. Now that it's out that it is needed, I doubt very much they will be able to attract good people until it's confirmed.

God knows how long it will be before appointments are made or the durability results eventually trundle in though.

I still live in a fantasy world where I dream that the sudden placing turns out to be the last stumbling block to striking the mythical deal for NXP002 with the Asian partner who has been waiting patiently in the wings all this time.

Foolish nonsense, I know.

Scary when you remember that fact, isn't it!?

All those directors who couldn't stand the heat and scurried away when they were needed most should be the ones fielding the blame for the situation we are in. They are the ones who have destroyed confidence in this company.

I hope that AR is made of stronger stuff and has the cojones to finally put things back on track.

Some of the buy prices appear to be at or below 1p...could just be limit orders being triggered

"Makes you wonder why Jo Holland or DG hasn't sold any."

Dunno Soup. They haven't shown support by buying anymore either.

I often wonder why they both walked away at crucial points but kept hold of shares in a firm they no longer controlled. Perhaps the voting rights are still useful in pushing through or rejecting resolutions that they like/don't like.

Thanks for the warm tribute Whimax ;O)

If it's comedy you're after though, perhaps you should take a look back at some of the news feeds for the company in late 2019. Pure comedy gold in hindsight! It's a bit like watching Ricky Gervais' Afterlife though...it makes want to laugh and cry at the same time.

It almost feels like someone doesn't want that stake-building to occur Hale.

Nothing ever seems to happen that adds value. Everything is always shrouded in mystery and uncertainty to the extent that it is almost impossible for the market to assess true worth.

For example, we still don't know the terms of the Oxilio deal. We know we've had 2 small up fronts of 25k each. We are now waiting to see what the milestones will be but they're obviously not substantial enough to avert another placing. So the big question is, how much revenue will OXL001 have to generate in order to hit the full 2m cap on royalties? Is it 10m, 100m, 1bn? We have no idea. One wonders if Trx might eventually make more out of it than we will.

Then there is the uncertainty surrounding the CEO and business development role which is still ongoing despite most of the data coming in 2 months ago and Allenby themselves mentioning it as a serious issue.

It's beginning to feel like NFX has turned into a life-support machine which is just being used to keep the products alive while allowing them to be developed as far as possible before all funding options dry up. I just hope that a big fish who is willing to a pay a reasonable price gets whiff of this and puts us out of our misery before some small chancer outfit moves in and steals our IP for a pittance.

Monday sees the end of January. It remains to be seen whether or not we'll actually see the durability data as promised in the proactive video. My guess is that they're probably more interested in getting that 2nd tranche approved than they are on recruiting key people or getting CRO's to keep to deadlines.

Looks like the bid has just dipped below 1p too.

Deep joy!

"If you can find a solution to the fickle nature of traders not seeing value in a share "

It's not just the fickle traders though, is it?

Why has this company not been snapped up at this price if it has 2 potential blockbusters for which there has been data available for nearly 2 months now?

I've not much left to lose.

Slightly off-topic but the TRx Biosciences website appears to be up and running.

https://trxbiosciences.com/teams/

I was just curious as to what they might be working on. They seem to be very busy. As well as the partnerships we already know about, they appear to have a list of wholly owned products that they are working on which appear to cover: anti-inflammatory for a lung disorder, cancer, Irritable bowel (I think) and depression.

The team page lists Dan Gooding as a co-founder and executive director. Strangely, he doesn't seem to be registered as an official 'person' at companies house though:

https://find-and-update.company-information.service.gov.uk/company/11986839/officers

I thought all directors need to be registered but maybe there are exceptions.

I wonder what Joanne Holland is up to these days. She left us to pursue a career as a free-lancer. Doesn't seem to be much in the way of updates to her profile since though.

Probably just the last of the 2%ers who bought in prior getting stung by the placing RNS.

It's so quiet now that most of them appear to have moved on.

LoL, I'll eat it with relish if I'm wrong.

I agree with SSM though. Once people are in place and all results are in then maybe things will change.

I'm not holding my breath for that Mars.

They have said early 2022 instead of January. I will eat my hat if those results come in before the end of January.